Ursodeoxycholic acid combined with bezafibrate in the treatment of refractory primary biliary cholangitis:a meta-analysis
10.3760/cma.j.issn.l007-3418.2019.04.012
- VernacularTitle:熊去氧胆酸联合苯扎贝特治疗难治性原发性胆汁性胆管炎的Meta分析
- Author:
Bailei FENG
1
;
Huihong YU
;
Wei SHEN
Author Information
1. 重庆医科大学附属第二医院消化内科 400010
- Keywords:
Bezafibrate;
Liver cirrhosis,biliary;
Deoxycholic acid;
Meta-analysis
- From:
Chinese Journal of Hepatology
2019;27(4):304-311
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy,safety and remission rates of pruritus of bezafibrate and UDCA combination therapy in the treatment of refractory PBC.Methods PubMed,Embase,The Cochrane Library databases,Science direct,Web of Science,CBM,WangFang Data,CNKI,VIP databases were searched to collect randomized controlled trials,crossover trials and self-control clinical trials of combination therapy of UDCA and bezafibrate with UDCA monotherapy for PBC up to June,2018.RevMan 5.3 software was used for meta-analysis.Two evaluators independently screened the literature,extracted the data,and evaluated the risk of bias of relevant study.Results Eleven studies,including 465 patients were included.Ursodeoxycholic acid combined with bezafibrate had greatly improved liver biochemical indicators(P<0.01)and pruritus scores in patients with refractory primary biliary cholangitis(MD=-2.97,95% CI:-4.34～-1.60,P<0.01).However,there was no statistically significant differences in adverse events(RR=1.28,95% CI:0.96 to 1.70,P=0.09),and mortality rate(RR=2.58,95% CI:0.57 to 11.73,P=0.22)between the two groups.Conclusion Ursodeoxycholic acid combined with bezafibrate may improve the biochemical response and pruritus score of refractory PBC,but has no significant effect on adverse events and mortality rate.
